This is a surgical procedure that helps the heart pump better. Doctors take a muscle from your back (the latissimus dorsi) and use it to support the heart's pumping action. They attach this muscle to the heart and use an electrical device to make it contract along with the heart.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Cardiomyoplasty, usually called dynamic cardiomyoplasty, was an experimental heart failure operation that used one of the body's own muscles as a helper pump. Surgeons moved the latissimus dorsi, the broad muscle across the back, into the chest while keeping its blood and nerve supply attached, wrapped it around the weakened heart and connected it to an implanted stimulator, a pacemaker-like device that made the muscle squeeze in time with the heartbeat. The idea was that the extra squeeze would help a failing heart pump, and that the wrap would keep the heart from stretching larger. The operation was first performed in 1985 and was offered to adults with severe heart failure that had not improved with the best available medicines, most often because of an enlarged, weakened heart muscle (dilated cardiomyopathy) or damage from earlier heart attacks. More than a thousand people had it worldwide. It is no longer performed. The only randomized trial and long-term follow-up found that, although some people felt better, the wrap did not reliably improve how well the heart pumped or help people live longer, and surgeons worldwide abandoned it. Today, people with advanced heart failure are treated with combinations of heart failure medicines, implanted devices that correct heart rhythm or coordinate the heartbeat, surgery for blocked arteries or leaking valves when those are part of the problem, mechanical heart pumps called ventricular assist devices, and heart transplantation. Someone reading about cardiomyoplasty now is most likely living with a past operation or exploring older treatment ideas, and a heart failure specialist is the right person to discuss current options. The term cellular cardiomyoplasty refers to a separate research approach using injected cells, not this muscle wrap operation.
Because cardiomyoplasty was reserved for people with severe heart failure, preparation centered on deciding whether someone was well enough to survive a major chest operation. Teams assessed heart function, lung pressures and overall strength, and learned that the sickest patients, especially those short of breath even at rest, did much worse. This led centers to limit the operation to people whose heart failure was serious but not yet at its most advanced stage. As with other major heart surgery, the team reviewed medicines, blood clotting and other health problems in advance and explained the long recovery and muscle training period that would follow.
The operation was done under general anesthesia. The surgeon freed the latissimus dorsi from the back, leaving it attached to its artery and nerve, then passed it into the chest through an opening in the chest wall. The muscle was wrapped around the main pumping chambers of the heart and stitched in place. Electrodes on the muscle were connected to the stimulator, a device placed under the skin that timed the muscle's contractions to the heartbeat. In most cases the heart did not need to be stopped and a heart-lung machine was not used.
Recovery involved both healing from major surgery on the chest and back and a slow training process for the transplanted muscle. Skeletal muscle tires quickly, unlike heart muscle, so the stimulator was turned on gradually over the following weeks with bursts of electrical pulses. This conditioning changed the muscle so it could contract with every heartbeat, or every other beat, without wearing out. Follow-up visits were needed to check and adjust the stimulator. People who had cardiomyoplasty still had heart failure and continued heart failure medicines and regular cardiology care. Some later received an implanted defibrillator because of the risk of dangerous heart rhythms, and some went on to heart transplantation. A previous cardiomyoplasty does not rule out a later transplant, and in one series long-term survival after such transplants was similar to that after other heart transplants.
The main risk was death around the time of surgery. Reported early death rates ranged from about 3 to 10 percent within 30 days in reviews, and one large French series of 212 patients reported 14 percent dying in hospital, with risk closely tied to how advanced the heart failure was. A frequently quoted summary of the problem was that the people healthy enough to survive the operation often did not need it, while those who needed it most could not survive it. After surgery, sudden cardiac death from abnormal heart rhythms and worsening heart failure remained common causes of death. In the French series, about a third of later deaths were sudden. The stimulator could fail and need replacing. The benefit did not outweigh these risks. In the Cardiomyoplasty-Skeletal Muscle Assist Randomized Trial (C-SMART), the only randomized trial comparing the operation with medicines alone, people who had the operation reported better symptoms, but there was no difference in survival at one year, and the trial stopped early in 1998 because too few people enrolled. Improvements in ejection fraction (the share of blood the left ventricle pumps out with each beat) were small. This combination of real surgical risk and unproven benefit is why the procedure was abandoned.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Cardiomyoplasty, what to expect, or ask the community a question.